1. Home
  2. /
  3. Projects
  4. /
    5. Page 2

Acceptability

Acceptability refers to meeting the policymakers, end-users, and health system requirements for a new TB vaccine for adults and adolescents. This  includes defining values from various populations, engaging communities as partners in decision-making, and having robust communication strategies in place. This follows from the WHO global framework for country introduction of new adolescent and adult TB vaccines (https://www.who.int/publications/m/item/who-global-framework-to-prepare-for-country-introduction-of-new-tb-vaccines-for-adults-and-adolescents)

Prevention is better than cure’: a mixed methods study of communities’ and healthcare workers’ perspectives on new adult and adolescent TB vaccines and their implementation in Zambia

2024
Hypothetical vaccines
Mixed methods study examining community members' and healthcare workers' views on future TB vaccines for adults and adolescents in Zamibia. It assesses willingness to receive a TB vaccine, preferred vaccine characteristics, concerns about safety and efficacy, trusted information sources, barriers to uptake, and preferred approaches for vaccine delivery and implementation.

Acceptability of and confidence in novel tuberculosis vaccines among adults living with HIV

2026
Hypothetical vaccines
Objective: Several novel tuberculosis vaccines (NTVs) are being evaluated in clinical trials. Understanding the perception of acceptability and confidence in NTVs will inform implementation strategies. Conclusion: NTV acceptability was high amongst these PWH, and they preferred community-based delivery models. Our findings may inform strategies to increase implementation of NTVs among PWH in South Africa.

Scoping Community Interventions to Support New TB Vaccine Introduction: From Grassroots Partnerships to Global Policymaking

2024-2025
To assess the role of communities and civil society in shaping TB vaccine introduction policies, implementation and equitable access. Aim 1: Map the structures, networks, and major players active in TB civil society and overlay these with the policy pipeline for new TB vaccines. Aim 1: Map the structures, networks, and major players active in TB civil society and overlay these with the policy pipeline for new TB vaccines. Aim 2: work with members of the regional community advisory boards (rCABs) established with support from the USAID-funded SMART4TB project to produce country policy portraits illustrating how TB and immunization policy is made in selected countries and the points where community and civil society actors can intervene. Aim 3: work with the rCAB in the Eastern Europe and Central Asia (EECA) region to explore interventions by community and civil society to ensure equitable access to new TB vaccines. All three Aims will be completed in relation to the ECVP and the Global Framework for Country Introduction of New TB Vaccines.

Prep4TBVax

2023-2025
M72/AS01e, MTBVAC
New TB vaccines are likely to be crucial in addressing the ongoing TB pandemic. With multiple promising vaccine candidates in the pipeline and the earliest availability of a candidate expected by 2028, it is of outmost importance that once available, the vaccine can be implemented rapidly and effectively. Limited research has looked at the delivery strategies available to provide a new TB vaccine to beneficiaries and therefore, this study assesses the acceptability and feasibility of delivery strategies for the vaccine candidates M72/AS01e and MTBVAC in Ethiopia, Nigeria, and Tajikistan.

New tuberculosis vaccines are in late-stage trials, but how confident is the public in high burden countries in vaccines?

With tuberculosis (TB) vaccine candidates in late-stage trials, it is important to prepare for implementation to avoid delays upon licensure. General confidence in vaccines has been identified as an anticipated barrier to introducing new TB vaccines. In the absence of detailed TB specific vaccine acceptability and confidence data, we analysed currently available vaccine confidence data in countries appearing on one of the World Health Organization (WHO) high burden lists to investigate vaccine confidence in countries with a high TB burden
Load More
Click to copy link of this header Menu